Nantahala Capital Management LLC Raises Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Nantahala Capital Management LLC boosted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 23.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 560,532 shares of the company's stock after acquiring an additional 107,300 shares during the quarter. Nantahala Capital Management LLC owned 0.66% of Syndax Pharmaceuticals worth $7,410,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of SNDX. Virtus ETF Advisers LLC grew its position in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after buying an additional 827 shares during the last quarter. E Fund Management Co. Ltd. grew its holdings in Syndax Pharmaceuticals by 14.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after purchasing an additional 1,583 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after purchasing an additional 1,732 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth $26,000. Finally, Y Intercept Hong Kong Ltd increased its position in Syndax Pharmaceuticals by 2.5% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock valued at $1,101,000 after buying an additional 1,995 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SNDX. StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank cut their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. Citigroup lowered their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. increased their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $36.20.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is owned by company insiders.

Syndax Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ SNDX traded down $0.09 during midday trading on Friday, reaching $13.73. 2,274,577 shares of the stock were exchanged, compared to its average volume of 1,610,207. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -3.78 and a beta of 0.82. The firm has a 50-day simple moving average of $12.89 and a two-hundred day simple moving average of $14.71. Syndax Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).